Apr 04

The analysis will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

Antonarakis and co-workers demonstrated that mCRPC in men who had AR-V7 in circulating tumor cells was resistant to the hormone drugs enzalutamide and abiraterone. Prior research in prostate cancer mouse models has linked AR-V7 with resistance to taxane chemotherapy also. Thus, the existing study was carried out to discover if these results from preclinical experiments would be validated in patients with mCRPC.As part of the annual wellness check out, the proposal claims that ‘optional components, if appropriate, could include a cognitive impairment screening and administration of or referral for appropriate Medicare-covered immunizations and screening exams, among others.’ All enrolled beneficiaries would be qualified to receive the wellness visit once every full year beginning in 2011, and no co-payment or deductible would apply. Within six months of completing the assessment, Medicare would pay for a visit to a primary treatment provider to create a personalized prevention program. Related StoriesApplying a top restaurant model to healthcare communications: an interview with Brandi Robinson, SanofiAddressing standard of living needs in prostate malignancy: an interview with Professor Louis DenisRE.WORK showcases future technology and innovations in deep learning softwareIn a written report, ‘Memory Matters,december ‘ released last, AFA underscored the worthiness of memory space screenings, noting that current research supports screening while a ‘safe, cost-efficient intervention that may reassure the healthy person, promote successful aging and, when indicated, direct individuals to appropriate clinical assets.’ At the right time, Hall said the report serves as a ‘wake up call’ to the general public and medical professionals, as well as to policymakers.